NCT03795558View on ClinicalTrials.gov

A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 21, 2021

Study Completion Date

March 1, 2022

Conditions
End Stage Renal Disease
Interventions
DRUG

Etelcalcetide

Up-Titration

Trial Locations (1)

4020

Ordensklinikum Linz GmbH Elisabethinen, Linz

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Prim. Priv. Doz. Dr. Daniel Cejka

OTHER

NCT03795558 - A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients | Biotech Hunter | Biotech Hunter